登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，5月5日，Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-05-06

  • Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study

    Dongze Li, You Chen, Hong Liu, Yu Jia, Fanghui Li, Wei Wang, Jiang Wu, Zhi Wan, Yu Cao & Rui Zeng

    Signal Transduction and Targeted Therapy volume 5, Article number: 62 (2020)

    A series of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since the end of 2019 is ongoing and triggering a global public health crisis. The estimated case fatality rate is approximately 3.4% in China. However, some patients experience dyspnea within 1 week and develop rapidly to organ injury and even death within 2 weeks after dyspnea.1 In addition, early organ injury could lead to higher risks of mortality. Thus, early identification of patients at risk of organ injury and death is crucial, which saves the patients from classified and invasive treatment, improving clinical outcome and prognosis. The human immune system plays significant roles in the resistance of foreign pathogens and the progress of pneumonia.

  • 原文来源：https://www.nature.com/articles/s41392-020-0163-5
20浏览量
原文链接
相关报告

  • 《JAMA，3月25日，Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-26
    • Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Shaobo Shi, MD1,2,3; Mu Qin, MD4; Bo Shen, MD1,2,3; et alYuli Cai, MD5; Tao Liu, MD1,2,3; Fan Yang, MD6; Wei Gong, MMSC7; Xu Liu, MD, PhD4; Jinjun Liang, MD, PhD1,2,3; Qinyan Zhao, MD, PhD1,2,3; He Huang, MD, PhD1,2,3; Bo Yang, MD, PhD1,2,3; Congxin Huang, MD, PhD1,2,3 Author Affiliations Article Information JAMA Cardiol. Published online March 25, 2020. doi:10.1001/jamacardio.2020.0950 Abstract Importance Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited. Objective To explore the association between cardiac injury and mortality in patients with COVID-19. Design, Setting, and Participants This cohort study was conducted from January 20, 2020, to February 10, 2020, in a single center at Renmin Hospital of Wuhan University, Wuhan, China; the final date of follow-up was February 15, 2020. All consecutive inpatients with laboratory-confirmed COVID-19 were included in this study.
    100浏览量
    原文链接

  • 《Lancet，5月28日，Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-29
    • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M Kuderer, MD † Toni K Choueiri, MD † Dimpy P Shah, PhD † Yu Shyr, PhD † Samuel M Rubinstein, MD Donna R Rivera, PharmD et al. Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31187-9 Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.
    138浏览量
    原文链接